scholarly journals Antimuscarinic Agent

2020 ◽  
Author(s):  
Keyword(s):  
Antimuscarinic Agent

ChemInform Abstract: Preparation and Properties of the Enantiomers of the Selective Antimuscarinic Agent 1-Cyclohexyl-1-phenyl-4-piperidino-1-butanol (Hexahydro-Difenidol).

ChemInform ◽  
1989 ◽  
Vol 20 (18) ◽  
Author(s):  
R. TACKE ◽  
C. STROHMANN ◽  
S. SARGE ◽  
H. K. CAMMENGA ◽  
D. SCHOMBURG ◽  
...  
Keyword(s):  
Antimuscarinic Agent

M 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland

2002 ◽  
Vol 366 (2) ◽  
pp. 97-103 ◽  
Author(s):  
Ken Ikeda ◽  
Seiji Kobayashi ◽  
Mami Suzuki ◽  
Keiji Miyata ◽  
Makoto Takeuchi ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Urinary Bladder ◽  
The Novel ◽  
Antimuscarinic Agent ◽  
Receptor Antagonism

scholarly journals Effect of beperadium iodide (SX-810), a novel antimuscarinic agent, on gastric mucosal lesions in rats

1987 ◽  
Vol 43 ◽  
pp. 232
Author(s):  
Katsuyoshi Kawashima ◽  
Kaori Yamaguchi ◽  
Yoshiaki Ochi ◽  
Makoto Oka ◽  
Toshiaki Kadokawa
Keyword(s):  
Antimuscarinic Agent ◽  
Gastric Mucosal Lesions ◽  
Mucosal Lesions

Usefulness of pirenzepine, an M1 antimuscarinic agent, for effort myocardial ischemia

1992 ◽  
Vol 69 (17) ◽  
pp. 1407-1411 ◽  
Author(s):  
Paolo Marraccini ◽  
Enrico Orsini ◽  
Guido Nassi ◽  
Claudio Michelassi ◽  
Antonio L'Abbate
Keyword(s):  
Myocardial Ischemia ◽  
Antimuscarinic Agent

scholarly journals A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients

Toxins ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 365 ◽  
Author(s):  
Yi-Huei Chang ◽  
Po-Jen Hsiao ◽  
Huang Chi-Ping ◽  
Hsi-Chin Wu ◽  
Po-Fan Hsieh ◽  
...  
Keyword(s):  
Urinary Incontinence ◽  
Botulinum Toxin ◽  
Adverse Events ◽  
Observational Study ◽  
Botulinum Toxin A ◽  
Mixed Urinary Incontinence ◽  
Efficacy And Safety ◽  
Toxin A ◽  
Antimuscarinic Agent ◽  
Significant Difference

This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients received MUS only and MUS with BoNT-A injection, respectively. The efficacy outcome included change in Urinary Incontinence Outcome Scores (UIOS), change in Overactive Bladder Symptom Score (OABSS), and use of antimuscarinic agent or beta-3 agonist. Safety assessments included adverse events including urinary retention, increased postvoid residual volumes, and urinary tract infection. MUS with BoNT-A injection was insignificantly better than MUS only in urinary incontinence outcome (88% vs. 71%, respectively, p = 0.085) at week three. Among the 33 patients with detrusor overactivity (DO), patients who received BoNT-A had a higher cure rate of incontinence (88% vs. 41%, p = 0.01) and less required antimuscarinic agent or beta-3 agonist (31% vs. 94%, p < 0.001) compared to patients who did not receive BoNT-A injection. There was no significant difference in the incidences of adverse events between two groups. BoNT-A injection with MUS demonstrated efficacy and safety in the treatment of mixed urinary incontinence, specifically for women with DO.

Efficient and single pot process for the preparation of enantiomerically pure solifenacin succinate, an antimuscarinic agent

2011 ◽  
Vol 142 (11) ◽  
pp. 1181-1186 ◽  
Author(s):  
Navnath C. Niphade ◽  
Kunal M. Jagtap ◽  
Anil C. Mali ◽  
Pavankumar V. Solanki ◽  
Madhukar N. Jachak ◽  
...  
Keyword(s):  
Antimuscarinic Agent ◽  
Enantiomerically Pure ◽  
Solifenacin Succinate

Tolterodine-A New Bladder-Selective Antimuscarinic Agent

1998 ◽  
pp. 964
Author(s):  
L. Nilvebrant ◽  
K.-E. Andersson ◽  
P.-G. Gillberg ◽  
M. Stahl ◽  
B. Sparf
Keyword(s):  
Antimuscarinic Agent

scholarly journals The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy

2018 ◽  
Vol 10 (8) ◽  
pp. 243-256 ◽  
Author(s):  
Karl-Erik Andersson ◽  
Nurul Choudhury ◽  
Jean-Nicolas Cornu ◽  
Moses Huang ◽  
Cees Korstanje ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Combination Therapy ◽  
Combination Treatment ◽  
Primary Objective ◽  
Antimuscarinic Agent ◽  
Antimuscarinic Agents ◽  
Related Quality ◽  
Health Related ◽  
Bothersome Symptom ◽  
Clinical Benefits

Urgency is the prevalent and most bothersome symptom of overactive bladder (OAB) and the treatment of urgency is the primary objective in the management of OAB. Urgency has a major impact on other symptoms of OAB and culminates in an increased frequency of micturition and reduced volume voided, which may contribute to shorter intervals between the need to void. Antimuscarinic agents and mirabegron, a β3-adrenoceptor agonist, constitute the main oral pharmacotherapeutic options for the treatment of urgency and other OAB symptoms. The reduction of urgency and other OAB symptoms significantly improve health-related quality of life. This review will explore the distinct mechanisms of action and effects of antimuscarinic agents and mirabegron, in relation to their effect on the pathophysiology of urgency. The review will also provide an overview of the various validated measurements of urgency and the numerous clinical trials regarding antimuscarinic agent monotherapy, mirabegron monotherapy, or combination treatment with mirabegron added on to the antimuscarinic agent solifenacin. A narrative review of the literature relating to pathophysiology of urgency, the validated measurements of urgency, and clinical trials relating to the pharmacological treatment of urgency. Antimuscarinic agent monotherapy, mirabegron monotherapy, or combination treatment with mirabegron added on to the antimuscarinic agent solifenacin statistically significantly reduce the symptoms of urgency compared with placebo. Combination therapy with mirabegron added on to solifenacin also statistically significantly reduces the symptoms of severe urgency compared with antimuscarinic agent monotherapy. A critique of the clinical benefits of combination therapy is also provided. Combination therapy provides an alternative treatment in patients with OAB that includes urgency who respond poorly to first-line monotherapy and who may otherwise often move on to more invasive treatments.

Sign in / Sign up

Export Citation Format

Share Document